Long-term coronary endothelial function after zotarolimus-eluting stent implantation: A 9 month comparison between zotarolimus-eluting and sirolimus-eluting stents

International Heart Journal

Volumn 49, Issue 6, 2008, Pages 639-652

  Shin, Dong Il ^a   Seung, Ki Bae ^a   Kim, Pum Joon ^a   Chang, Kiyuk ^a   Choi, Jae Kee ^a   Jeon, Doo Soo ^a   Kim, Mi Jeong ^a   Lee, Man Young ^a   Chung, Wook Sung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acetylcholine; Drug eluting stent (DES); Endothelium; Vasoconstriction; Zotarolimus eluting stent (ZES)

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRATE; PACLITAXEL; RAPAMYCIN; TICLOPIDINE; ZOTAROLIMUS; DRUG DERIVATIVE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; EQUIPMENT DESIGN; FEMALE; HUMAN; INTERMETHOD COMPARISON; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; TREATMENT RESPONSE; ADRENERGIC SYSTEM; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

CORONARY VESSELS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; SIROLIMUS; VASOMOTOR SYSTEM;

EID: 60249102323     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.639     Document Type: Article

References (34)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
2. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxeleluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109: 1942-7.
3. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004; 109: 487-93.
4. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II Trial. Circulation 2006; 114: 798-806.
5. Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006; 27: 166-70.
6. Fuke S, Maekawa K, Kawamoto K, et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 2007; 71: 220-5.
7. Togni M, Raber L, Cocchia R, et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 2007; 120: 212-20.
8. Shin DI, Kim PJ, Seung KB, et al. Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction. Int Heart J 2007; 48: 553-67.
9. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-2.
10. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-541.
11. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007; 100: 36M-44. (Review)
12. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006; 48: 2440-7.
13. Sakurai R, Bonneau HN, Honda Y, Fitzgerald PJ. Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. Am J Cardiol 2007; 100: 71M-6.
14. Miyazawa A, Ako J, Hongo Y, et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008; 155: 108-13.
15. Maseri A, Davies G, Hackett D, Kaski JC. Coronary artery spasm and vasoconstriction. The case for a distinction. Circulation 1990; 81: 1983-91. (Review)
16. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111-8.
17. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-8.
18. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 7-17. (Review)
19. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75. (Review)
20. Lamontagne D, König A, Bassenge E, Busse R. Prostacyclin and nitric oxide contribute to the vasodilator action of acetylcholine and bradykinin in the intact rabbit coronary bed. J Cardiovasc Pharmacol 1992; 20: 652-7.
21. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46: 231-6.
22. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277-83.
23. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-5.
24. Kotani J, Awata M, Nanto S, et al. Incomplete neointinal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47: 2108-11. (Review)
25. Sousa JE, Costa MA, Farb A, et al. Images in cardiovascular medicine. Vascular healing 4 years after the implantation of sirolimus-eluting stent in humans: a histopathological examination. Circulation 2004; 110: e5-6.
26. Inoue T, Sata M, Hikichi Y, et al. Mobilizaton of CD34-positive bone marrow-derived cells after coronary stent implantation?: impact on restenosis. Circulation 2007; 115: 553-61.
27. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
28. Obata J, Kitta Y, Takano H, et al. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol 2007; 50: 1305-9.
29. Matsunaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, Chilian WM. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000; 102: 3098-103.
30. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 2006; 19: 405-13. (Review)
31. Joner M, Finn A, Kolodgie F, et al. Lack of neointimal growth is a predictor of late stent thrombosis. Circulation 2006; 114: II-453. (abstract)
32. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103: 2816-21.
33. Simon C, Palmaz JC, Sprague EA. Influence of topography on endothelialization of stents: clues for new designs. J Long Term Eff Med Implants 2000; 10: 143-51.
34. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83: 338-45.